@syntaxin.com
Syntaxin engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allIcon
JPEG
About
Description
Syntaxin, based in the United Kingdom, is a biopharmaceutical company specializing in the development of innovative protein therapeutics. The company was founded in 2001 by Professor Peter H. March, Dr.
Patrick M. Cullen, and Sir Richard J. Roberts.
Its headquarters are located in Oxford, England. The main focus of Syntaxin's research and development is on creating treatments for neurological and metabolic disorders. The company utilizes its proprietary technology called SNAP-tag to design and produce novel protein therapeutics that target specific biological pathways.
These therapeutics have the potential to address unmet medical needs and improve patient outcomes. Syntaxin operates on a global scale, working with partners and collaborators to advance its therapeutic candidates. The company has established strong relationships with leading academic institutions, pharmaceutical companies, and research organizations worldwide.
Notably, Syntaxin has formed joint ventures with several renowned entities, including Roche and Oxford University. In terms of market position, Syntaxin has positioned itself as a pioneer in the field of protein therapeutics. The company's innovative approach and promising pipeline have garnered attention within the biopharmaceutical industry.
While specific sales figures are not publicly available, Syntaxin is known to have achieved significant funding through partnerships and investments. In recent years, Syntaxin has achieved several noteworthy milestones. The company has expanded its product lineup, successfully advancing multiple therapeutic candidates into the clinic.
Additionally, Syntaxin has made strategic partnerships and collaborations to further strengthen its research and development efforts. As of the latest available information, Syntaxin continues to operate as a leading biopharmaceutical company. The company remains focused on advancing its protein therapeutics pipeline and forging new partnerships to bring innovative treatments to patients in need.
Unfortunately, no further updates or key information specific to the company's current status are available at this time
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories